The emerging role of miR-375 in cancer

International Journal of Cancer

Volumn 135, Issue 5, 2014, Pages 1011-1018

  Yan, Jun Wei ^a   Lin, Ju Sheng ^a   He, Xing Xing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

cancer; microRNA; miR 375; tumor suppressor

Indexed keywords

CYCLIC AMP; GLUCOSE; MICRORNA 375; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP1; TUMOR MARKER;

AEG 1 GENE; CANCER PROGNOSIS; CARCINOGENESIS; DNA METHYLATION; DOWN REGULATION; ESOPHAGUS CANCER; GENE EXPRESSION REGULATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HUMAN; IGF1R GENE; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PDK1 GENE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; YAP1 GENE;

CANCER; MICRORNA; MIR-375; TUMOR SUPPRESSOR;

3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASES; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL ADHESION MOLECULES; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASMS; PHOSPHOPROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, IGF TYPE 1;

EID: 84902548164     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28563     Document Type: Review

References (99)

1. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-9.
2. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436: 740-4.
3. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
4. Lewis BP, Burge CB, Bartel DP,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
5. Gregory RI, Chendrimada TP, Cooch N, et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005; 123: 631-40.
6. Lewis BP, Shih I-h, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-98.
7. Iorio MV, Ferracin M, Liu C-G, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
8. Ozen M, Creighton C, Ozdemir M, et al. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2007; 27: 1788-93.
9. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647.
10. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-22.
11. Su H, Yang J-R, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-42.
12. Ma L, Teruya-Feldstein J, Weinberg RA,. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-8.
13. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432: 226-30.
14. Kloosterman WP, Lagendijk AK, Ketting RF, et al. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol 2007; 5: e203.
15. El Ouaamari A, Baroukh N, Martens GA, et al. miR-375 targets 3-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008; 57: 2708-17.
16. Poy MN, Hausser J, Trajkovski M, et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A 2009; 106: 5813-8.
17. Erener S, Mojibian M, Fox JK, et al. Circulating miR-375 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 2013; 154: 603-8.
18. van de Bunt M, Gaulton KJ, Parts L, et al. The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. PloS One 2013; 8: e55272.
19. He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 2012; 31: 3357-69.
20. Ding L, Xu Y, Zhang W, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 2010; 20: 784-93.
21. Mathé EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009; 15: 6192-200.
22. Avissar M, Christensen BC, Kelsey KT, et al. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15: 2850-5.
23. Chang C, Shi H, Wang C, et al. Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett 2012; 531: 204-8.
24. Emdad L, Lee S-G, Su ZZ, et al. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci 2009; 106: 21300-5.
25. Yoo BK, Emdad L, Su Z-z, et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009; 119: 465.
26. Yu C, Chen K, Zheng H, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis 2009; 30: 894-901.
27. Hu G, Chong RA, Yang Q, et al. MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer. Cancer Cell 2009; 15: 9-20.
28. Mazure NM, Pouysségur J,. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol 2010; 22: 177-80.
29. Mathew R, Karantza-Wadsworth V, White E,. Role of autophagy in cancer. Nature Rev Cancer 2007; 7: 961-7.
30. Chang Y, Yan W, He X, et al. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012; 143: 177-87 e8.
31. Jin S, White E,. Role of autophagy in cancer: management of metabolic stress. Autophagy 2007; 3: 28-31.
32. Rabinowitz JD, White E,. Autophagy and metabolism. Science 2010; 330: 1344-8.
33. Liu AM, Poon RT, Luk JM,. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010; 394: 623-7.
34. Du Y, Xu Y, Ding L, et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J gastroenterol 2009; 44: 556-61.
35. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266.
36. Rotkrua P, Akiyama Y, Hashimoto Y, et al. MiR-9 downregulates CDX2 expression in gastric cancer cells. Int J Cancer 2011; 129: 2611-20.
37. Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 2010; 70: 2339-49.
38. Tzivion G, Gupta VS, Kaplun L, et al. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006; 16: 203-13.
39. Li X, Lin R, Li J,. Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig Dis Sci 2011; 56: 2849-56.
40. Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61: 33-42.
41. Hsu PP, Sabatini DM,. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-7.
42. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
43. Cairns RA, Harris IS, Mak TW,. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
44. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
45. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7: 261-9.
46. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541.
47. Lee S, Su Z, Emdad L, et al. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 2007; 27: 1114-21.
48. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008; 371: 1695-709.
49. Hui AB, Bruce JP, Alajez NM, et al. Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res 2011; 17: 7539-50.
50. Harris T, Jimenez L, Kawachi N, et al. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 2012; 180: 917-28.
51. Kinoshita T, Hanazawa T, Nohata N, et al. The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. J Hum Genet 2012; 57: 556-63.
52. Kinoshita T, Nohata N, Yoshino H, et al. Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int J Oncol 2012; 40: 185-93.
53. Friboulet L, Barrios-Gonzales D, Commo F, et al. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res 2011; 17: 5562-72.
54. Nishikawa E, Osada H, Okazaki Y, et al. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res 2011; 71: 6165-73.
55. Wang F, Li Y, Zhou J, et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol 2011; 179: 2580-8.
56. Szczyrba J, Nolte E, Wach S, et al. Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res 2011; 9: 791-800.
57. de Souza Rocha Simonini P, Breiling A, Gupta N, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010; 70: 9175-84.
58. Jonsdottir K, Janssen SR, Da Rosa FC, et al. Validation of Expression Patterns for Nine miRNAs in 204 Lymph-Node Negative Breast Cancers. PloS One 2012; 7: e48692.
59. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro N, Fineberg S, Kenny PA, Loudig O,. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol 2012; 226: 108-19.
60. Croce CM,. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.
61. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-60.
62. Keller DM, McWeeney S, Arsenlis A, et al. Characterization of pancreatic transcription factor Pdx-1 binding sites using promoter microarray and serial analysis of chromatin occupancy. J Biol Chem 2007; 282: 32084-92.
63. Avnit-Sagi T, Kantorovich L, Kredo-Russo S, et al. The promoter of the pri-miR-375 gene directs expression selectively to the endocrine pancreas. PloS One 2009; 4: e5033.
64. Hark AT, Schoenherr CJ, Katz DJ, et al. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000; 405: 486-9.
65. Ohlsson R, Renkawitz R, Lobanenkov V,. CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 2001; 17: 520-7.
66. Furuta M, Kozaki KI, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-76.
67. Mazar J, DeBlasio D, Govindarajan SS, et al. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett 2011; 585: 2467-76.
68. Du Y, Liu Z, Gu L, et al. Characterization of human gastric carcinomarelated methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo. BMC Cancer 2012; 12: 249.
69. Keller DM, Clark EA, Goodman RH,. Regulation of microRNA-375 by cAMP in pancreatic beta-cells. Mol Endocrinol 2012; 26: 989-99.
70. Wang G, Jones S, Marra M, et al. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene 2006; 25: 7311-23.
71. Kok M, Zwart W, Holm C, et al. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011; 125: 1-12.
72. Zhao Q, Tao J, Zhu Q, et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia 2003; 18: 285-92.
73. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98.
74. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
75. Wang G-K, Zhu J-Q, Zhang J-T, et al. Circulating microRNA:a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. European Heart J 2010; 31: 659-66.
76. Wang S, Wang L, Bayaxi N, et al. A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut 2013; 62: 280-9.
77. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
78. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
79. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucl Acids Res 2011; 39: 7223-33.
80. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423-33.
81. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008; 105: 10513-8.
82. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505.
83. Taylor DD, Gercel-Taylor C,. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
84. Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-60.
85. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-9.
86. Komatsu S, Ichikawa D, Takeshita H, et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011; 105: 104-11.
87. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010; 70: 9798-807.
88. Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010; 127: 2870-8.
89. Komatsu S, Ichikawa D, Takeshita H, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther 2012; 12 Suppl 1: S53-9.
90. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012; 106: 768-74.
91. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009; 15: 6192-200.
92. Li J, Li X, Li Y, et al. Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PloS One 2013; 8: e53582.
93. Zhang X, Yan Z, Zhang J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol 2011; 22: 2257-66.
94. Brase JC, Wuttig D, Kuner R, et al. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010; 9: 306.
95. Kong YW, Ferland-McCollough D, Jackson TJ, et al. microRNAs in cancer management Lancet Oncol 2012; 13: e249-58.
96. Nohata N, Hanazawa T, Kikkawa N, et al. Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum Genet 2011; 56: 595-601.
97. Wilting SM, Verlaat W, Jaspers A, et al. Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics 2013; 8: 220-8.
98. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120: 1046-54.
99. Faltejskova P, Svoboda M, Srutova K, et al. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012; 16: 2655-66.